Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.
Journal: JCO oncology advances
Published: May 18, 2026
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Journal: Cancer
Published: August 07, 2023
Reply to T. Shimoi et al and Y. Shimanuki et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 23, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 07, 2021
Graves' disease causing pancytopenia and autoimmune hemolytic anemia at different time intervals: a case report and a review of the literature.
Journal: Case reports in medicine
Published: July 08, 2013
Showing 1-5 of 5
Last Updated: 09/26/2026